|
Diagnosis: Neuroblastoma,
poorly differentiated subtype |
|
Neuroblastoma |
|
Definition |
|
|
|
Clinical Futures |
-
Belong to the family of
neuroblastic tumors that include ganglioneuromas,
ganglioneuroblastomas and neuroblastomas. Neuroblastic tumors
are of the sympathetic nervous system that originates from
neural crest sympathogonia.
-
Neuroblastoma is the most
common extracranial pediatric solid neoplasm and the third most
common pediatric malignancy after leukemia and CNS tumors. The
incidence in USA is about 8.7 per million.
-
Most cases (88%) less than
5-year-old, median age 21 months.
-
Neuroblastomas can arise
from anywhere along the sympathetic chain. They most commonly
occur in the adrenal medulla (35-38%). Usually only one adrenal
gland is involved, and bilateral involvement is rare, followed
by extraadrenal in the abdomen (30%), and thorax (14-20%).
-
They have been associated
with a number of disorders, such as Hirschsprung disease, fetal
alcohol syndrome, DiGeorge syndrome, Von Recklinghausen disease,
and Beckwith-Wiedemann syndrome.
-
Approximately 45-54% of
patients with neuroblastoma have a palpable abdominal mass.
These patients may have abdominal pain. Nearly 10% of patients
develop hypertension as a result of renal vein compression.
Hypertension in patients with neuroblastoma may also be related
to renal arterial compression and excess catecholamine
production. Extradural extension of neuroblastomas can present
with focal or diffuse paralysis and bowel or bladder
dysfunction. Pelvic neuroblastomas can also cause bowel or
bladder dysfunction.
-
Unusual manifestations or
associations with childhood neuroblastoma: (1), "blueberry
muffin" baby with cutaneous metastasis; (2), opsoclonus/myoclonus,
2-7%; (3), alopecia; (4), heterochromia iridis; (5), Horner's
syndrome; (6), Watery diarrhea due to secretion of VIP, 6%; (7),
Asymmetric crying syndrome; (8), Cushing's syndrome.
-
Two thirds of patients
with neuroblastoma present with metastases at the time of
diagnosis. Hutchinson syndrome: bone metastases with limping
and irritability. Pepper syndrome: massive liver metastases.
|
|
Gross Findings |
-
Gross specimens of
neuroblastomas can appear well circumscribed or infiltrative.
They do not have capsules. They range from minute nodules or in
situ lesions to large masses weighing more than 1 kg.
-
Calcification may be
apparent on gross inspection as punctuate, opaque foci, or a
gritty sensation.
|
|
Microscopic Findings |
-
Architectural patterns:
lobular growth with delicate and often incomplete fibrovascular
septa (not as well developed as in pheochromocytoma); May have
more diffuse or solid areas;
-
Cytological morphology:
tumor cells are small, round or ovoid with little cytoplasm;
nuclei are dark with small indistinct nucleoli, and the
chromatin is dispersed with a "salt and pepper" pattern.
Homer-Wright rosettes, circular, ovoid or angular zones of
pale-stained fibrillary material that is surrounded by tumor
cells. They are typical of neuroblastomas but are not present in
all cases.
-
Alterations in stroma:
hemorrhage, necrosis, calcification or cystic changes can be
present.
-
Three histology subtypes
-
Neuroblastoma, undifferentiated:
-
Tumor cells:
small-to-medium in size, with indiscernible-to-thin rims
of cytoplasm and vaguely defined cytoplasmic borders.
-
Nuclei: vary in
shape, rounded to elongated, salt-and-pepper chromatin,
may contain distinct nucleoli.
-
Absent background
neuropil.
-
Neuroblastoma, poorly
differentiated:
-
Neuroblastoma,
differentiating:
|
|
Differential Diagnosis |
-
Ewing's sarcoma:
t(11;22)(q24;q12)
-
Desmoplastic small round
cells tumor: t(11;22)(p13;q12 or q11.2)
-
Malignant rhabdoid tumor.
-
Acute lymphocytic/myeloid lymphoma/leukemia
for undifferentiated neuroblastoma.
-
Pheochromocytoma
|
|
Immunohistochemical Findings |
-
Positive for NSE,
chromogranin A, synaptophysin, microtubule-associated proteins
(MAP-1 or MAP-2), S100+ in stellate to dendritic cells adjacent
to the vessels;
|
|
Electron Microscope |
|
|
|
Cytogenetic Studies |
-
Del(1p36.1-2 )
-
N-myc amplification
|
|
Prognosis |
-
Age: better prognosis if <1.5 years
old.
-
MKI: <2% good prognosis, 2-4%
intermediate, >4% unfavorable.
-
N-MYC amplification,
unfavorable prognosis. N-MYC is a proto-oncogene located on
chromosome arm 2p. If it is present in multiple copies (10 or
more), it promotes rapid tumor growth and indicates a bad
prognosis.
-
Del(1p36.1-2) , bad
prognpsis. This deletion
causes rapid tumor growth due to a presumed loss of a tumor
suppressor gene, indicating a bad prognosis.
-
Cells with normal or near
normal DNA content (DNA index = 1) are associated with
aggressive tumor activity. Hyperdiploid cells (DNA index >1) are
associated with a better prognosis since this DNA complement may
stimulate the proliferation of Schwann cells and promote
maturity.
More stroma, less nodules
of immature neuroblastic cells, better prognosis.
-
High HVA, good prognosis.
Neuroblastomas exhibit a great variety of tumor biologic
behaviors that can be used to determine a patient's prognosis.
About 95% of neuroblastomas secrete catecholamines (vanillylmandelic
acid [VMA] and homovanillic acid [HVA]). HVA is a dopamine
metabolite and is a more mature catecholamine than VMA, which is
a metabolite of epinephrine and norepinephrine. Increased levels
of HVA in the urine are correlated with maturity of the tumor
and an improved prognosis. Nearly 7% of neuroblastomas secrete
vasoactive intestinal peptide (VIP). These tumors are more
mature; therefore, patients with VIP-producing tumors have a
prognosis better than that of other patients. Elevated levels of
serum ferritin (>142 ng/mL) and neurospecific enolase (>100 ng/mL)
are associated with a bad prognosis.
|
|
Reference |
-
Rha SE, Byun JY, Jung SE,
et al: Neurogenic tumors in the abdomen: tumor types and imaging
characteristics. Radiographics 2003 Jan-Feb; 23(1): 29-43
-
AFIP, Tumor of the adrenal
gland and extra-adrenal paraganglia, 3rd series
-
http://www.webpathology.com/
(For gross and slides of ganglioneuroma)
-
http://www.emedicine.com/radio/topic293.htm
-
http://www.emedicine.com/RADIO/topic472.htm
-
Cancer 1999;86:349-63
|